Reactivation of developmentally expressed p63 isoforms predisposes to tumor development and progression

Cancer Research

Volumn 66, Issue 8, 2006, Pages 3981-3986

  Koster, Maranke I ^a   Lu, Shi Long ^b   White, Lisa D ^a   Wang, Xiao Jing ^b,c   Roop, Dennis R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; NERVE CELL ADHESION MOLECULE; PROTEIN P63; TRANSCRIPTION FACTOR TWIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FLOW CYTOMETRY; GENE SWITCHING; GENOMIC INSTABILITY; HUMAN; HUMAN TISSUE; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CARCINOGENESIS; SPINDLE CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH;

ANIMALS; CADHERINS; CARCINOMA, SQUAMOUS CELL; CELL ADHESION MOLECULES; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENOMIC INSTABILITY; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; PHOSPHOPROTEINS; PROTEIN ISOFORMS; PROTO-ONCOGENES; SKIN NEOPLASMS; TRANS-ACTIVATORS; TWIST TRANSCRIPTION FACTOR;

EID: 33646245191     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0027     Document Type: Article

References (23)

1. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with trans-activating, death-inducing, and dominant-negative activities. Mol Cell 1998;2:305-16.
2. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999;398:708-13.
3. Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development Nature 1999;398:714-8.
4. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
5. Flores ER, Sengupta S, Miller JB, et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005;7:363-73.
6. Mills AA. p63: oncogene or tumor suppressor? Curr Opin Genet Dev 2006;16:38-44.
7. Perez-Losada J, Wu D, Delrosario R, Balmain A, Mao JH. p63 and p73 do not contribute to p53-mediated lymphoma suppressor activity in vivo. Oncogene 2005;24:5521-4.
8. Liefer KM, Koster MI, Wang XJ, Yang A, McKeon F, Roop DR. Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. Cancer Res 2000;60:4016-20.
9. Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR. p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev 2004;18:126-31.
10. Nischt R, Roop DR, Mehrel T, et al. Aberrant expression during two-stage mouse skin carcinogenesis of a type I 47-kDa keratin, KI3, normally associated with terminal differentiation of internal stratified epithelia. Mol Carcinog 1988;1:96-108.
11. Wersto RP, Liblit RL, Koss LG. Flow cytometric DNA analysis of human solid tumors: a review of the interpretation of DNA histograms. Hum Pathol 1991;22:1085-98.
12. Lu SL, Reh D, Li AG, et al. Overexpression of transforming growth factor β1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Res 2004;54:4405-10.
13. DiGiovanni J. Multistage carcinogenesis in mouse skin. Pharmacol Ther 1992;54:63-128.
14. Roop DR, Krieg TM, Mehrel T, Cheng CK, Yuspa SH. Transcriptional control of high molecular weight keratin gene expression in multistage mouse skin carcinogenesis. Cancer Res 1988;48:3245-52.
15. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
16. Reis-Filho JS, Carrilho C, Valenti C, et al. Is TTF1 a good immunohistochemical marker to distinguish primary from metastatic lung adenocarcinomas? Pathol Res Pract 2000;196:835-40.
17. Quintanilla M, Brown K, Ramsden M, Balmain A. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 1986;322:78-80.
18. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117:927-39.
19. Hazan RB, Qiao R, Keren R, Badano I, Suyama K. Cadherin switch in tumor progression. Ann N Y Acad Sci 2004;1014:155-63.
20. Rosivatz E, Becker I, Specht K, et al. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol 2002;161:1881-91.
21. Johnson RA, Shepard EM, Scotto KW. Differential regulation of MDR1 transcription by the p53 family members. Role of the DNA binding domain. J Biol Chem 2005;280:13213-9.
22. Park BJ, Lee SJ, Kim JI, et al. Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res 2000;60:3370-4.
23. Urist MJ, Di Como CJ, Lu ML, et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 2002;161:1199-206.